Resources

FAST's mission extends beyond guiding potential therapeutics through the drug development pipeline. We also aspire to share our accumulated knowledge with those who have an interest in participating in AS treatment development. Our aim is to prevent redundant efforts and the waste of valuable time and resources by providing insights and expertise to others in this space.

FAST Bioresources

FAST's has curated bioresources for industry and research partners with the goal of offering resources, insights, and catalog available tools to streamline therapeutic development for the field.

If you are interested in learning more about any of the following resources, please contact us at science@cureangelman.org.

FAST Angelman Syndrome Literature Repository!

This interactive repository serves as a dynamic, visual tool for exploring AS literature. Developed to assist researchers, clinicians, and stakeholders, it organizes publications, studies, and reviews in an accessible network, where relationships among clinical presentation, genotype, model of study, and FAST pillar become immediately clear.

Key Features:

• Visual Mapping: Our Kumu repository organizes literature through visual maps, making it easy to identify connections between articles, authors, and topics.

• Filter and Focus Options: Filter content by age, FAST pillar, organism of study, genotype, phenotype, study type, or specific keywords to dive into particular areas of interest.

• Collaborative Potential: The repository encourages a collaborative environment, making it easy to share insights and discuss new ideas with colleagues or identify gaps in the research where research is critical.

• Coming soon: As this is an evolving repository, newly published work will be added when available. We are excited to be adding additional categorization groups including 1. Therapeutic modality, 2. Natural History Study, 3. Drug delivery, 4. Biomarkers and endpoints, 5. Clinical assessments (EEG, sleep, seizure, ORCA, Bayley, Vineland, etc.), 6. Economic burden, 7. Newborn screening, 8. Model genotype, 9. Age of model, and 10. Keystone publications that established a proof of concept for therapeutic approach.

Whether you're delving into emerging research trends, reviewing foundational studies, or exploring a niche within AS, this repository aims to facilitate deeper understanding and inspire impactful discoveries. Dive in, explore the FAST literature repository, and let it serve as a guide for your next research endeavors.

Angelman Syndrome Biomarker and Outcome Measure (A-BOM) Consortium

The A-BOM Consortium is made up of a team of over 350 people that have interest in advancing the regulatory science for Angelman syndrome to understand, develop, test, and validate different tools that can assess meaningful clinical outcomes for individuals living with Angelman syndrome.

For more information about A-BOM, please visit here.

Rush F.A.S.T. Center for Translational Research

In December 2022, FAST announced a $5 million gift to establish the new clinical trial and translational research effort for rare neurodevelopmental disorders, a first-of-its-kind flagship center to be directed by Dr. Elizabeth Berry-Kravis.

Named the Rush F.A.S.T. Center for Translational Research, it will be the global headquarters for training individuals in how to run neurogenetic clinical trials and deliver innovative interventional therapies that require novel delivery methods and specialized care.

Learn more by clicking here.